|
Aug 7
|
Galapagos Creates New Subscription Right Plan
|
|
Aug 6
|
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
|
|
Jul 27
|
Galapagos Second Quarter 2025 Earnings: Misses Expectations
|
|
Jul 23
|
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation
|
|
Jul 23
|
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors
|
|
Jul 23
|
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update
|
|
Jun 12
|
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL
|
|
Apr 1
|
Biotech stocks slide as Marks resignation seen being negative for sector
|
|
Feb 14
|
Galapagos NV (GLPG) (FY 2024) Earnings Call Highlights: Strategic Shifts and Financial Resilience
|
|
Feb 12
|
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
|
|
Feb 12
|
Galapagos NV (GLPG): A Cheap Biotech Stock to Invest In Now
|
|
Sep 30
|
Galapagos receives transparency notification from EcoR1 Capital
|
|
Aug 28
|
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
|
|
Jun 14
|
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
|
|
Jun 14
|
Retail investors are Galapagos NV's (AMS:GLPG) biggest owners and were hit after market cap dropped €74m
|
|
May 6
|
Galapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript
|
|
May 4
|
Galapagos First Quarter 2024 Earnings: EPS: €0.36 (vs €0.35 in 1Q 2023)
|
|
Jan 2
|
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
|
|
Dec 19
|
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
|
|
Dec 9
|
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
|